Clinical Trial Search

Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale

Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months

Primary: Increase of Interferon Gamma Levels — 0 Participants

Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants

Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants

Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Progression-Free Survival — 7.71 weeks

Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Number of Participants Experiencing the Incidence of Grade One or Higher Adverse Events — 12 participants

Primary: Progression of Disease — 14 Participants

Primary: Response Rate

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants

Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants

Primary: Recruitment for CALM — 14; 14; 12 Participants

Primary: Marginal-failure Rate — 0 percentage of failure rate

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants

Primary: Mean Difference in Change of Depressive Symptoms Using the Patient-Reported Outcomes Measurement Information System (PROMIS) -Depression Scale in Primary Central Nervous…